A major clinical trial (STOMP) published in the New England Journal of Medicine found that tecovirimat, an FDA-approved smallpox drug, did not improve mpox resolution in outpatient adults with clade II mpox. The randomized, placebo-controlled study of 412 participants showed 79% clinical resolution in the tecovirimat group versus 81% in the placebo group by day 29, with no significant differences in pain reduction or lesion healing.

Healthcare stocks have been stagnant since April, but offer attractive dividend yields ranging from 5.3% to 7.1%. The article highlights several healthcare REITs and pharmaceutical companies with high dividend potential despite market challenges.

SIGA Technologies reported strong Q2 2025 financial performance, with revenue jumping 271.6% to $81.1 million, driven by major TPOXX antiviral therapy deliveries to U.S. government agencies. The company paid a special $0.60 per share dividend and maintained robust cash reserves.

The sustainable construction materials market is predicted to reach $734.9 billion by 2032, driven by the growing adoption of green certifications and standards. Companies are focusing on team training and understanding green benchmarks to strengthen their position in the evolving market. However, the adoption of sustainable materials faces challenges, including higher initial costs and varying standards across countries.

SIGA Technologies, a biopharmaceutical company, is facing scrutiny over its disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox. The company's clinical trial for TPOXX® failed to meet its primary endpoint, leading to a significant drop in the stock price. SIGA also terminated its Chief Medical Officer, raising further concerns about the company's transparency.

SIGA Technologies' lead product TPOXX failed to meet its primary endpoint in a clinical trial for Mpox treatment, leading to a significant drop in the company's stock price. The company also terminated its Chief Medical Officer, raising further concerns about transparency.

SIGA Technologies, Inc. (SIGA) is under investigation by the Law Offices of Howard G. Smith due to potential violations of federal securities laws. The investigation is related to the termination of the company's Chief Medical Officer and the subsequent release of a video revealing concerns about the company's Monkeypox treatment.

The article discusses three pharmaceutical companies with potential to meet the demand for mpox vaccines: Bavarian Nordic, Emergent Biosolutions, and SIGA Technologies. It highlights their vaccine and treatment candidates, recent developments, and stock performance.

The PALM 007 clinical trial for SIGA's tecovirimat in treating monkeypox did not meet its primary endpoint, but showed potential benefits for patients treated early and those with severe disease. The safety profile was comparable to placebo. Additional trials are ongoing to further evaluate tecovirimat's efficacy.

SIGA Technologies, Inc. announced that the U.S. Department of Health and Human Services exercised a procurement option for the delivery of approximately $113 million of oral TPOXX® treatment courses, enhancing orthopoxvirus preparedness.

Siga Technologies Inc. (SIGA) closed the most recent trading day at $6.41, moving +1.42% from the previous trading session.

Further Advances SIGA’s Strategy to Expand Access to TPOXX into More International Markets Further Advances SIGA’s Strategy to Expand Access to TPOXX into More International Markets